ArticleFrontiers in public health2026
Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Finotonlimab combined with bevacizumab demonstrated superior progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma. However, its economic value in different healthcare systems has not been fully characterized. This study evaluated the cost-effectiveness of finotonlimab plus bevacizumab from the perspectives of U.S. payers and the Chinese healthcare system. A Markov state-transition model was constructed using clinical efficacy data from a phase 3 randomized controlled trial. Methods: Health state utilities were obtained directly from trial data, and cost inputs were derived from published sources and country-specific charge databases. The outcomes included quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net health benefits (INHBs), and incremental net monetary benefits (INMBs). Scenario analyses, deterministic and probabilistic sensitivity analyses, and price simulations were performed to assess the robustness and cost-effectiveness across predefined willingness-to-pay (WTP) thresholds. Results: In the base-case analysis, the ICER of finotonlimab plus bevacizumab compared with sorafenib was $27,505.33 per QALY in China and $138,055.71 per QALY in the U.S., both below the corresponding WTP thresholds of $40,354.27 and $150,000 per QALY, respectively. The associated INHBs were 0.26 QALYs in China and 0.07 QALYs in the U.S., with INMBs of $10,523.82 and $10,684.73, respectively. Probabilistic sensitivity analysis indicated that combination therapy was cost-effective in 91.43% of simulations in China and 58.33% in the United States. Price simulation analyses suggested that finotonlimab would remain cost-effective in the U.S. setting when priced below $9,157.84 per 200 mg. Conclusion: From both Chinese and U.S. payer perspectives, finotonlimab plus bevacizumab represents a cost-effective first-line treatment strategy for unresectable hepatocellular carcinoma. These findings offer quantitative support for pricing and reimbursement decisions related to this emerging immunotherapy combination targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.